SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will host a virtual roadshow webinar on Tuesday September 20, 2022, at 4:30 p.m. Eastern Time.
During the webinar, a new video showcasing the HeartBeam AIMIGo platform technology for use in heart attack detection will be unveiled. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.
The video is available in the company’s investor relations section here.
The video takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology, a medical grade solution with a 510(K) regulatory pathway that the company expects to submit to FDA for clearance by the end of the year. Once cleared, for the first time outside of a medical setting, the Company believes that AIMIGo can enable patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be initiated, if needed. The goal of HeartBeam’s technology is to offer more accurate heart attack detection to triage patients and expedite treatment and save healthcare dollars.
HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Business Officer Jon Hunt, PhD, will host the virtual roadshow webinar, during which they will review recent announcements, including its 510(k) application to the FDA for its HeartBeam AIMI™ platform technology, ongoing initiatives and discuss key 2022 and 2023 milestones. The webinar will be accompanied by a presentation and followed by a question-and-answer session from webcast viewers, which can be accessed via the webcast link.
To access the webinar, please use the following information:
Date: |
Tuesday September 20, 2022 |
||
Time: |
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
||
Dial-in: |
1-877-704-4453 |
||
International Dial-in: |
1-201-389-0920 |
||
Conference Code: |
13732771 |
||
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1569585&tp_key=156ad0b0f4 |
A telephone replay will be available approximately two hours after the call and will run through December 20, 2022, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13732771. The replay can also be viewed through the webinar webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack. For more information, visit www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
